Von willebrand factor in diabetic angiopathy

Diabetes and Metabolism

Volumn 24, Issue 4, 1998, Pages 327-336

  Kessler, L ^a,b   Wiesel, M L ^a   Attali, P ^a   Mossard, J M ^a   Cazenave, J P ^a   Finget, M ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Hopital Central Strasbourg   (France)

Author keywords

Angiopathy; Diabetes; Endothelial dysfunction; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR;

DIABETIC ANGIOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRINOLYSIS; GLYCOSYLATION; HEMOSTASIS; HUMAN; PEPTIDE SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; MODELS, CARDIOVASCULAR; VON WILLEBRAND FACTOR;

EID: 0031711586     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Decken T, Yokoyama H, Mathicscn E. Cohort study of predictive value of urinary albumin excretion for atherosclerosic vascular disease in patients with insulin-dependent diabetes Br Med J, 1996, 312, 871-874.
2. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in non-insulin-dependent diabetes mellitus. Diabetes, 1995, 44, 1301-1309.
3. Stehouwer CDA, Schaper NC. The pathogenesis of vascular complications of diabetes mellitus : one voice or many ? Eur J Clin Invest, 1996, 26, 535-543.
4. Stehouwer CDA, Lambert J, Donker AJM, Van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res, 1997, 34, 55-68.
5. Blann AD. Von Willebrand factor and atherosclerosis. J Int Med, 1995, 237, 432-434.
6. Bar RS. Vascular endothelium and diabetes mellitus. In : Spaet TH, ed. "Progress in Haemost. Thromb." 1992, 363-381.
7. Zimmerman TS, Ratnoff OD, AEP. Immunologic differentition of classic hemophilia (Factor VIII deficiency) and von Willebrand's disease. With observations on combined deficiencies of antihemoplilic factor and proaccelerin (Factor V) and on an acquired circulating anticoagulant against antihemoplilic factor. J Clin Invest, 1971, 40, 244-254.
8. Ruggeri ZM, Ware J. Von Willebrand factor. Faseb J, 1993, 7, 308-316.
9. Meyer D. Von Willebrand factor : a target for inhibition of thrombosis. J Exp Clin Hematol, 1993, 35, 255-257.
10. Meyer D. Von Willebrand factor : Structure and function. Thromb Haemost, 1993, 70, 99-104.
11. Heywood DM, Mansfield MW, Grant PJ. Levels of Von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus, Diab Med, 1996, 13, 720-725.
12. Wu XX, Gordon RE, RWG, Kuo HJ, Uson RR, Rand JH. Morphological relationships of von Willebrand factor type VI collagen and fibrillin in human vascular subendothelium. Am J Path, 1996, 149, 283-291.
13. Blann AD, Bushell D, Davies A, Faragher EB. Miller JP, McCollum CN. Von Willebrand factor, the endothelium and obesity. Int J Obes Relat Metab Disorders, 1993, 17, 723-725.
14. Sobel M, Bird KE, Tylercross R et al. Heporins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation, 1996, 93, 992-999.
15. Fleming TG. Von Willebrand factor: its function and its measurement in the laboratory. British J Biomed Sci, 1995, 52, 50-57.
16. Katayama M, Hirai S, Kato I, Titani K. Immunoenzymometric analysis for plasma von Willebrand factor degradation in diabetes mellitus using monoclonal antibodies recognizing protease-sensitive sites. Clin Biochem, 1994, 27, 123-131.
17. Muntean WE, Borkcnstein MH, Haas J. Elevation of factor VIII coagulant activity over factor VIII coagulant antigen in diabetic children without vascular disease. A sign of activation of the factor VIII coagulant moiety during poor diabetes control. Diabetes, 1985, 34, 140-144.
18. Stehouwer CD, Fischer HR, Van Kuijk AW, Polak BC, Donker AJ. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes, 1995, 44, 561-564.
19. Stehouwer CD, Nauta JJ, Zeldenrusl GC, Hackeng WH, Donker AJ, Den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet, 1992, 340, 319-323.
20. Plater ME, Ford I, Dent MT, Preston FE, Ward JD. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia, 1996, 39, 336-343.
21. Newrick PG, Wilson AJ, Jakuboowski J, Boultopn AJM, Ward JD. Sural nerve oxygen tension in diabetes. BMJ, 1986, 293, 1053-1054.
22. Malik RA, Tesfaye S, Thompson SD. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia, 1993, 36, 454-459.
23. Stehouwer CD, Zellenrath P, Polak BC et al. Von Willebrand factor and early diabetic retinopalhy : no evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion. Diabetologia, 1992, 35, 555-559.
24. O'Rourke M. Arterial stiffness, systolic blood pressure and logical treatment of arterial hypertension. Hypertension, 1990, 15, 339-347.
25. Blann AD, McCollum CN. Von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surgery, 1994, 8, 10-15.
26. Blann AD, Waite MA. Von Willebrand factor and soluble E-selectin in hypertension : influence of treatment and value in predicting the progression of atherosclerosis. Coronary Artery Disease, 1996, 7, 143-147.
27. Conlan MG, Folsom AR, Finch A et al. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. Thromb Haemost, 1993, 70, 380-385.
28. Nakano H, Yamada K, Nishimura M et al. Effect of hypercholesteremia on vascular endothelial function and albumin excretion rate in patients with diabetes mellitus. Jap J Nephrol, 1996, 38, 507-512.
29. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin-dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost, 1994, 72, 979-984.
30. Blan A. Von Willcbrand factor and the endothelium in vascular disease. British J Biomed Sci, 1993, 50, 125-134.
31. Dc Fronzo RA, Ferranini E. Insulin resistance : a multifacetcd syndrome responsible for NIDDM. obesity, hypertension, dyslipidemia, and athrerosclerotic cardiovascular disease. Diabetes Care, 1991, 14, 173-194.
32. Ferri C, Bellini C, Desideri G, Plasma endothelinl levels in obese hypertensive and normotensive men. Diabetes, 1995, 44, 431-436.
33. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction : cause of the insulin resistance syndrome. Diabetes, 1997, 46, 9-13.
34. Stehouwer CD, Stroes ES, Hackeng WH, Mulder PG, Den Ottolander GJ. Von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes, 1991, 40, 971-976.
35. Silveira AM, Sjoberg S, Blomback M, Ostman J. Von Willebrand factor antigen in plasma and urine in patients with type I (insulin-dependent) diabetes mellitus with and without nephropathy. J Diab & Compl, 1992, 6, 89-95.
36. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia, 1986, 29, 282-286.
37. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet, 1989, 1, 461-463.
38. Zimmermann J, Schramm L, Wanner C et al. Hemorheology, plasma protein composition and Von Willebrand factor in type I diabetic nephropathy. Clin Nephrol, 1996, 46, 230-236.
39. Porta M, La Selva M, Molnatti PA. Von Willebrand factor and endothelial abnormalities in diabetic microangiopathy. Diabetes Care, 1991, 14, 167-172.
40. Ford I, Singh TP, Kitchen S. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complication. Diabet Med, 1991, 8, 322-329.
41. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 43, 960-967.
42. Uuusitupa MIJ, Niskanen LK. Hyperglycemia and cardiovascular risk in NIDDM. Diabetes Care, 1995, 18, 884-885.
43. Ingerslcv J. 1995. Research methodologies in measurement of platelet function, endothelial proteins, coagulation factors and fibrinolysis. In : Mogensen CE, Standl E, eds. "Research methodologies in human diabetes". Berlin, New York, 1995, 125-146.
44. Standl E, Balletshofer B, Dahl B et al. Predictors of 10-year macrovascular and overall mortality in patients with NIIDM : the Munich General Practitioner Project. Diabetologia, 1996, 39, 1540-1545.
45. Williams B. Glucose-induced vascular smooth muscle dysfunction : the role of protein kinase C. J Hypertension, 1995, 13, 477-486.
46. Cerami A, Vlassarra H, Brownlee M. Protein glycosylation and the pathogenesis of atherosclerosis. Metabol, 1985, 34, 37-42.
47. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-B as a key mediator. Diabetes, 1995, 44, 1139-1146.
48. Ceriello A. Coagulation activation in diabetes mellitus : the role of hyperglycaemia and therapeutic prospects. Diabetologia, 1993, 36, 1119-1125.
49. Juhan-Vague I, Vague P. Hyperinsulinemia and its effects on coagulation and fibrinolysis in cardiovascular disease. Atheroscl Cardiovasc Disease, Haemost Endothel Function, 1992, 141-182.
50. De Meyer GRY, Herman AG. Vascular endothelial dysfunction. Progress in Cardiovasc Diseases, 1997, XXXIX, 325-342.
51. Kessler L, Wiesel ML, Boudjema K et al. Potential role of von Willebrand factor in the pancreatic venous thrombosis in simultaneous kidney and pancreas transplantation. Transplant Proc, 1997, 29, 2418-2419.
52. Greaves M, Pickering C, Knight G et al. Changes in the factor VIII complex in diabetic ketoacidosis : evidence of endothelial cell damage. Diabetologia, 1987, 30, 160-165.
53. Mordes DB, Lazarchick J, Colwell JA, Sens DA. Elevated glucose concentrations increase factor VIII R : Ag levels in human umbilical vein endothelial cells. Diabetes, 1983, 32, 876-878.
54. Husted SE, Nielsen HK, Bak JF, Beck-Nielsen H. Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment. Eur J Clin Investig, 1989, 19, 90-94.
55. Keys A, Menotti A, Karnoven MJ et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol, 1986, 124, 903-915.
56. Thomsen C, Rasmussen OW, Ingerslev J, Hermansen K. Plasma levels of von Willebrand factor in non-insulin-dependent diabetes mellitus are influenced by dietary monounsaturated fatty acids. Thromb Res, 1995, 77, 347-356.
57. Yao SK, Ober JC, Garfinkel LI et al. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis and delays coronary artery reocclusion in dogs. Circulation, 1994, 89, 2822-2828.
58. Takiguchi Y, Shimazawa M, Nakashima M. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs. B J Pharmacol, 1996, 118, 1633-1638.
59. Fressinaud E, Meyer D. Maladie de Willebrand. In : Sanpol J, Arnoux D, Boutière B, eds. "Manuel d'hémostase". Paris : Elsevier, 1995, 331-336.
60. Goodall AH. Advances in immunological aspects of vWF. In : Segatchian MJ, Sadvige GF, eds. "Biochemical, methodological and functional aspects". 1989, 79-89.